Clinical Trial Update: Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase II study of vismodegib in refractory or relapsed B-cell lymphoma or chronic lymphocytic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Erivedge (vismodegib)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Status: TERMINATED